A study, led by researchers at the UCLA Jonsson Comprehensive Cancer Center, found that targeting a metabolic process in people with a specific genetic mutation could help treat glioblastoma.
Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network, and Fred Hutchinson Cancer Center.
Positive high-level results from the FLAURA2 phase III trial showed Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Interim results from a first-in-human phase I clinical trial evaluating the safety, antitumor activity, and immunological characteristics of a genetically engineered natural killer T-cell immunotherapy for neuroblastoma showed that the treatment was well tolerated. Researchers also observed early evidence of strong antitumor activity.
Intratumoral delivery of an engineered oncolytic virus, DNX-2401, targeting glioblastoma cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional phase I/II clinical trial co-led by researchers at MD Anderson Cancer Center and the University of Toronto.
Women with early-stage cervical cancer had significantly higher chances of developing catheter-associated urinary tract infections after radical hysterectomies if they were smokers or used a catheter for more than seven days post-surgery, UT Southwestern Medical Center researchers found in a study.
Results from a phase I trial at Memorial Sloan Kettering Cancer Center suggest that treatment with mRNA vaccines (autogene cevumeran) cause an effective and lasting immune response in some patients with pancreatic cancer.
Researchers at the American Cancer Society, in an analysis of cancer death rates across all congressional districts in the U.S., found an overall decline in the past 25 years, with most districts showing a 20%-45% decline among males and a 10%-40% decline among females.
A recent clinical trial demonstrated that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy.
Immigrant adults with liver cancer in the U.S. have higher survival rates than people with the disease who were born in the U.S., according to research from the USC Norris Comprehensive Cancer Center.
